1. Sana Biotechnology facing class action for alleged securities fraud. 2. The lawsuit claims financial misrepresentation and operational risks. 3. Investors can seek to recover losses without upfront costs. 4. The firm has a strong track record in securities litigation.
The allegations of fraud typically lead to a drop in stock price. Historical examples show similar cases result in significant investor and market fallout.
Legal issues considerably impact investor confidence, directly affecting stock price.
Reaction to legal news often leads to immediate stock volatility, but longer-term effects depend on case judgments.
Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:
https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=141487&wire=4
SANA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
The filed complaint alleges that defendants made false statements and/or concealed that: (i) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (ii) SC291 in oncology, SC379, and SG299 were less promising than defendants had led investors to believe; (iii) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (iv) accordingly, defendants overstated Sana's financial capacity to maintain its current operations and advance its existing product candidates; and (v) as a result, defendants' public statements were materially false and/or misleading at all relevant times.
If you suffered a loss in Sana Biotechnology, Inc. during the relevant time frame, you have until May 20, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
SOURCE Levi & Korsinsky, LLP